Skip to content

Avastin for CNV Secondary to Pattern Dystrophy

Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00391144
Enrollment
5
Registered
2006-10-23
Start date
2006-07-31
Completion date
2006-10-31
Last updated
2006-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization Secondary to Pattern Dystrophy

Keywords

Pattern Dystrophy, Choroidal Neovascularization, Intravitreal Avastin Injection

Brief summary

The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but it seems that visual function may be preserved only in the short-term follow-up, with progressive deterioration thereafter. Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion, but unfortunately, this approach does not appear to guarantee long-term vision stabilization, and alternative therapies should be investigated.

Detailed description

Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin (1.25 mg) in operating room under sterile condition. Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT.

Interventions

PROCEDUREintravitreal triamcinolone injection of avastin (1.25 mg)

Sponsors

University of Trieste
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of RPD (hyperpigmented yellowish-greyish network, other family members sharing RPD, normal electroretinogram and normal/subnormal electrooculogram) * classic or occult CNV involving the foveal avascular zone's geometric centre

Exclusion criteria

* conditions other than RPD * intraocular surgery or capsulotomy within the last 2 or 1 months * pregnancy

Design outcomes

Primary

MeasureTime frame
number of eyes with <15 letter loss (approximately <3 lines) at 6-month examination compared with the baseline value
numeber of eyes with <15 letter loss at 12-month examinations, compared with the baseline value.

Secondary

MeasureTime frame
CNV progression
number of injections.

Countries

Italy

Contacts

Primary ContactMaurizio B Parodi, MD
maubp@yahoo.it+39 040 772449
Backup ContactGiuseppe Ravalico, MD
giuseppe.ravalico@aots.sanita.fvg.it+39 040 772449

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026